Detalhe da pesquisa
1.
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
N Engl J Med
; 379(24): 2342-2350, 2018 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30280658
2.
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
N Engl J Med
; 377(20): 1919-1929, 2017 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28885881
3.
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Lancet Oncol
; 19(4): 521-536, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29545095
4.
Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC.
JTO Clin Res Rep
; 5(3): 100638, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38455595
5.
Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).
Lung Cancer
; 151: 30-38, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33285469
6.
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study.
Lung Cancer
; 147: 137-142, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32702570
7.
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC.
J Thorac Oncol
; 15(2): 288-293, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31622733
8.
Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study.
J Thorac Oncol
; 14(8): 1390-1399, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31063864